MicroPort Scientific（MCRP.F）株式概要マイクロポート・サイエンティフィック・コーポレーションは、その子会社とともに、中華人民共和国、ヨーロッパ、中東およびアフリカ、日本、そして世界各国において、医療機器の革新、製造、販売に従事している。 詳細MCRP.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長3/6過去の実績2/6財務の健全性2/6配当金0/6報酬当社が推定した公正価値より68.7%で取引されている 収益は年間36.65%増加すると予測されています 今年は黒字化を達成 リスク分析株式の流動性は非常に低い 負債は営業キャッシュフローで十分にカバーされていない 財務結果に影響を与える大きな一時的項目 すべてのリスクチェックを見るMCRP.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW465,162 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA465,162 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$0.8512.2% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-478m2b2016201920222025202620282031Revenue US$1.9bEarnings US$83.3mAdvancedSet Fair ValueView all narrativesMicroPort Scientific Corporation 競合他社CONMEDSymbol: NYSE:CNMDMarket cap: US$1.5bOmnicellSymbol: NasdaqGS:OMCLMarket cap: US$1.6bLeMaitre VascularSymbol: NasdaqGM:LMATMarket cap: US$1.9bInspire Medical SystemsSymbol: NYSE:INSPMarket cap: US$1.8b価格と性能株価の高値、安値、推移の概要MicroPort Scientific過去の株価現在の株価HK$0.8552週高値HK$1.8552週安値HK$0.85ベータ0.361ヶ月の変化0%3ヶ月変化n/a1年変化-52.64%3年間の変化-60.17%5年間の変化-85.55%IPOからの変化0.28%最新ニュースお知らせ • Aug 19MicroPort Scientific Corporation to Report First Half, 2026 Results on Aug 31, 2026MicroPort Scientific Corporation announced that they will report first half, 2026 results on Aug 31, 2026お知らせ • Jul 01MicroPort Scientific Corporation Appoints Dr. Yingyao Chen as an Independent Non-executive DirectorMicroPort Scientific Corporation announced that at its AGM held on June 30, 2026, Dr. Yingyao Chen has been elected as an independent non-executive Director of the Company. His biographical details are set out below: Dr. Chen, born in 1968, is an expert in health technology assessment and hospital management. Dr. Chen currently serves as a Professor and Vice Dean of the School of Public Health, Fudan University, Director of the Key Laboratory of Health Technology Assessment of the National Health Commission, Director of the World Health Organization Collaborating Centre for Health Technology Assessment, Chairman of the Health Technology Assessment Professional Committee of the China Medicinal Biotech Association, Chairman of the Health Technology Assessment and Policy Research Professional Committee of the China Association for Medical Devices Industry, Vice Chairman of the Health Technology and Economic Evaluation Professional Committee of the China Health Economics Association, and Vice President of Shanghai Association for Maternal and Child Health and Improving Birth Outcome and Child Development. Dr. Chen has long been engaged in research in health technology assessment, hospital management and public health programme evaluation. He has led a number of research projects of the World Health Organization, the World Bank, the National Health Commission, the National Healthcare Security Administration, among others. Dr. Chen has served as chief editor of a number of national core textbooks, and has published extensively as first author or corresponding author in domestic and international core journals, including the British Medical Journal. From 1991 to 1999, Dr. Chen served as an Assistant Professor and Lecturer at the School of Public Health of Shanghai Medical University. From 1999 to 2001, he was a visiting scholar at the UCLA Fielding School of Public Health. Dr. Chen returned to the School of Public Health of Fudan University in 2001. Dr. Chen obtained his Bachelor's degree in Medicine and Master's degree in Medicine from Shanghai Medical University in 1991 and 1997, respectively, and obtained his Doctoral degree in Management from Fudan University in 2006.お知らせ • Jun 09MicroPort Scientific Corporation, Annual General Meeting, Jun 30, 2026MicroPort Scientific Corporation, Annual General Meeting, Jun 30, 2026, at 10:00 China Standard Time. Location: 1601 zhangdong road, zhangjiang hi-tech park, shanghai 201203, Chinaお知らせ • Mar 19MicroPort Scientific Corporation to Report Fiscal Year 2025 Results on Mar 31, 2026MicroPort Scientific Corporation announced that they will report fiscal year 2025 results on Mar 31, 2026お知らせ • Jan 23MicroPort Scientific Corporation Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025MicroPort Scientific Corporation provided consolidated earnings guidance for the year ended 31 December 2025. The Group is expected to achieve a turnaround to profitability for the year ended 31 December 2025 (the Period), recording a net profit of not less than USD 20 million (for the year ended 31 December 2024: audited net loss of approximately USD 268 million).お知らせ • Sep 22Shanghai MedTech Medical Equipment Partnership Enterprise completed the acquisition of 7.3% stake in MicroPort Scientific Corporation (SEHK:853) from Otsuka Medical Devices Co., Ltd.Shanghai MedTech Medical Equipment Partnership Enterprise reached an Share Transfer Agreement to acquire 7.3% stake in MicroPort Scientific Corporation (SEHK:853) from Otsuka Medical Devices Co., Ltd. on July 25, 2025. In related transaction, WeTron Capital Limited reached an Share Transfer Agreement to acquire an additional 7.3% stake in MicroPort Scientific from Otsuka Medical Devices and Goal Carol Limited, Jonathan W Chen and Jumbo Glorious Limited reached an Share Transfer Agreement to acquire 1.1% stake in MicroPort Scientific from Otsuka Medical Devices. Following the transaction, Otsuka Medical Devices will hold a 4.99% stake in MicroPort Scientific. The closing shall take place upon obtaining approval from relevant governmental authorities. BofA Securities, Inc. acted as financial advisor to Otsuka Medical Devices Co., Ltd. Shanghai MedTech Medical Equipment Partnership Enterprise completed the acquisition of 7.3% stake in MicroPort Scientific Corporation (SEHK:853) from Otsuka Medical Devices Co., Ltd on September 22, 2025.最新情報をもっと見るRecent updatesお知らせ • Aug 19MicroPort Scientific Corporation to Report First Half, 2026 Results on Aug 31, 2026MicroPort Scientific Corporation announced that they will report first half, 2026 results on Aug 31, 2026お知らせ • Jul 01MicroPort Scientific Corporation Appoints Dr. Yingyao Chen as an Independent Non-executive DirectorMicroPort Scientific Corporation announced that at its AGM held on June 30, 2026, Dr. Yingyao Chen has been elected as an independent non-executive Director of the Company. His biographical details are set out below: Dr. Chen, born in 1968, is an expert in health technology assessment and hospital management. Dr. Chen currently serves as a Professor and Vice Dean of the School of Public Health, Fudan University, Director of the Key Laboratory of Health Technology Assessment of the National Health Commission, Director of the World Health Organization Collaborating Centre for Health Technology Assessment, Chairman of the Health Technology Assessment Professional Committee of the China Medicinal Biotech Association, Chairman of the Health Technology Assessment and Policy Research Professional Committee of the China Association for Medical Devices Industry, Vice Chairman of the Health Technology and Economic Evaluation Professional Committee of the China Health Economics Association, and Vice President of Shanghai Association for Maternal and Child Health and Improving Birth Outcome and Child Development. Dr. Chen has long been engaged in research in health technology assessment, hospital management and public health programme evaluation. He has led a number of research projects of the World Health Organization, the World Bank, the National Health Commission, the National Healthcare Security Administration, among others. Dr. Chen has served as chief editor of a number of national core textbooks, and has published extensively as first author or corresponding author in domestic and international core journals, including the British Medical Journal. From 1991 to 1999, Dr. Chen served as an Assistant Professor and Lecturer at the School of Public Health of Shanghai Medical University. From 1999 to 2001, he was a visiting scholar at the UCLA Fielding School of Public Health. Dr. Chen returned to the School of Public Health of Fudan University in 2001. Dr. Chen obtained his Bachelor's degree in Medicine and Master's degree in Medicine from Shanghai Medical University in 1991 and 1997, respectively, and obtained his Doctoral degree in Management from Fudan University in 2006.お知らせ • Jun 09MicroPort Scientific Corporation, Annual General Meeting, Jun 30, 2026MicroPort Scientific Corporation, Annual General Meeting, Jun 30, 2026, at 10:00 China Standard Time. Location: 1601 zhangdong road, zhangjiang hi-tech park, shanghai 201203, Chinaお知らせ • Mar 19MicroPort Scientific Corporation to Report Fiscal Year 2025 Results on Mar 31, 2026MicroPort Scientific Corporation announced that they will report fiscal year 2025 results on Mar 31, 2026お知らせ • Jan 23MicroPort Scientific Corporation Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025MicroPort Scientific Corporation provided consolidated earnings guidance for the year ended 31 December 2025. The Group is expected to achieve a turnaround to profitability for the year ended 31 December 2025 (the Period), recording a net profit of not less than USD 20 million (for the year ended 31 December 2024: audited net loss of approximately USD 268 million).お知らせ • Sep 22Shanghai MedTech Medical Equipment Partnership Enterprise completed the acquisition of 7.3% stake in MicroPort Scientific Corporation (SEHK:853) from Otsuka Medical Devices Co., Ltd.Shanghai MedTech Medical Equipment Partnership Enterprise reached an Share Transfer Agreement to acquire 7.3% stake in MicroPort Scientific Corporation (SEHK:853) from Otsuka Medical Devices Co., Ltd. on July 25, 2025. In related transaction, WeTron Capital Limited reached an Share Transfer Agreement to acquire an additional 7.3% stake in MicroPort Scientific from Otsuka Medical Devices and Goal Carol Limited, Jonathan W Chen and Jumbo Glorious Limited reached an Share Transfer Agreement to acquire 1.1% stake in MicroPort Scientific from Otsuka Medical Devices. Following the transaction, Otsuka Medical Devices will hold a 4.99% stake in MicroPort Scientific. The closing shall take place upon obtaining approval from relevant governmental authorities. BofA Securities, Inc. acted as financial advisor to Otsuka Medical Devices Co., Ltd. Shanghai MedTech Medical Equipment Partnership Enterprise completed the acquisition of 7.3% stake in MicroPort Scientific Corporation (SEHK:853) from Otsuka Medical Devices Co., Ltd on September 22, 2025.お知らせ • Aug 19MicroPort Scientific Corporation to Report First Half, 2025 Results on Aug 29, 2025MicroPort Scientific Corporation announced that they will report first half, 2025 results on Aug 29, 2025お知らせ • Jul 18Microport Scientific Corporation Provides Earnings Guidance for the Six Month Ended 30 June 2025MicroPort Scientific Corporation provided earnings guidance for the six month ended 30 June 2025. The Group is estimated the revenue of the Group slightly decreased by no more than 4% year-on-year (excluding the effect of exchange rate). Among them, except the surgical robot business, all of the other major business segments recorded revenue decline or growth slowdown to varying extents.お知らせ • Apr 30Shanghai Fund Is Said to Weigh Buying Otsuka’s Stake in MicroPortA fund backed by Shanghai Industrial Investment (Holding) Co., Ltd. is in talks to buy Otsuka Holdings Co., Ltd. (TSE:4578)’s stake in Chinese medical device maker MicroPort Scientific Corporation (SEHK:853), according to people familiar with the situation. Otsuka has been considering options for its holding in Hong Kong-listed MicroPort, including selling it, Bloomberg News reported in October. The Japanese drugmaker’s stake was about 20.9% as of the end of June.お知らせ • Apr 29MicroPort Scientific Corporation, Annual General Meeting, May 30, 2025MicroPort Scientific Corporation, Annual General Meeting, May 30, 2025, at 10:00 China Standard Time. Location: 1601 zhangdong road, zhangjiang hi-tech park, shanghai 201203, Chinaお知らせ • Mar 18MicroPort Scientific Corporation to Report Fiscal Year 2024 Results on Mar 28, 2025MicroPort Scientific Corporation announced that they will report fiscal year 2024 results on Mar 28, 2025お知らせ • Aug 20MicroPort Scientific Corporation to Report First Half, 2024 Results on Aug 30, 2024MicroPort Scientific Corporation announced that they will report first half, 2024 results on Aug 30, 2024お知らせ • Jul 30MicroPort Scientific Corporation Announces Firesorb Bioresorbable Coronary Scaffold System Obtained Approval for Marketing from the NMPAThe board of directors of MicroPort Scientific Corporation announced that on 30 July 2024, the new generation Firesorb Bioresorbable Scaffold System (‘Firesorb Stent’), self- developed by the Group, obtained the approval for marketing from the National Medical Products Administration of China (the ‘NMPA’), which will further improve the Group's integrated, precise and intelligent holistic solutions for the diagnosis and treatment of coronary artery-related diseases, in order to serve the comprehensive needs of patients worldwide. About Firesorb Stent: First Target Eluting Bioresorbable Scaffold System with Reduced Strut Thickness to Same Level as Metal Stents While Maintaining Equal Support The Group adopted thin strut design which made Firesorb Stent the first target eluting bioresorbable scaffold system with reduced strut thickness to same level as metal stents while maintaining equal support. The Rate of Thrombosis of All Patients in the FUTURE-I, II and III Three Trials was only 0.32% at 2-year Follow up, with a Four-year Thrombotic Event of 0% in the RCT Study Data from large preclinical studies have shown that Firesorb Stent is non-inferior to permanent drug-eluting stents in terms of major clinical parameters from publicly available clinical data. Firesorb Stent has a target lesion failure (TLF) rate of only 4.3% at 4-year follow-up of RCT study. The rate of thrombosis of all patients in the FUTURE-I, II, and III Trials was only 0.32% at 2-year follow up, with four-year thrombotic event of 0% in the RCT study. The imaging results supports that Firesorb Stent is not inferior to other marketed permanent stents in terms of endothelial coverage rate and speed, and the numerical results of the clinical trial are superior compared to other biodegradable stents. Target Eluting Technology to Reduce Effective Drug Load while Achieving Same Efficacy Adopting the unique ‘target eluting’ technology of MicroPort, Firesorb Stent achieves precisely targeted drug application, coating only one side of the stent facing the vessel wall and reducing the effective drug load to one-third of the universal drug load while achieving the same efficacy. Wider Lesion Size Coverage As a bioresorbable stent with wider lesion size coverage and applicable to the treatment of small- vessel lesions up to 2.5 millimeters in diameter, Firesorb Stent solves the problem of accessibility of bioresorbable stent in small-vessel lesion areas. Meanwhile, the guidewire for rotational atherectomy, which is used in conjunction with the Group's first self-developed rotational atherectomy catheter system and coronary rotational atherectomy system, has recently obtained marketing approval from the NMPA, and the coronary rotational atherectomy system has entered the NMPA special review approval process for innovative medical devices (the ‘Green Path’). Impact on the Company. Improve the Diagnosis Holistic Medical Solutions for the Treatment of Cardiovascular Diseases to Bring New Growth Momentum The marketing approval of Firesorb Stent and guidewire for rotational atherectomy by the NMPA will further improve the Group's integrated, precise and intelligent holistic solutions for the diagnosis and treatment of coronary artery-related diseases, in order to serve the comprehensive needs of patients worldwide. Leveraging on the commercialisation capability of the Group's existing cardiovascular interventional product channels and overseas platforms, it is believed that new growth momentum will be brought to the Group. Strengthen the Leading Position in the Global Coronary Stent Field The incidence of coronary heart disease is trending younger. Bioresorbable stents, which can support diseased blood vessels in the short term and degrade completely in the body in the long term, are at the scientific and technological hub amid the global competition. The approval of Firesorb Stent will further strengthen the Group's leading position in the global coronary stent field. Application of Technologies Derived from Platform The technologies derived from Firesorb Stent platform are expected to be applied in other areas such as cerebral infarction, peripheral vascular stenosis, and bone trauma in the future, allowing more patients to access internationally leading treatment solutions.お知らせ • May 23Microport Scientific Corporation Announces Retirement of Non-Executive DirectorsThe Board of MicroPort Scientific Corporation announced that Dr. Qiyi Luo and Mr. Bo Peng, being non-executive directors of the Company, who did not offer themselves for re-election at the AGM in order to allow themselves to devote more time to their personal endeavours, have retired as non-executive directors of the Company at the conclusion of the AGM. Meanwhile, Dr. Qiyi Luo and Mr. Bo Peng have resigned as members of the strategy committee (the "Strategy Committee") of the Board at the conclusion of the AGM. Dr. Qiyi Luo and Mr. Bo Peng have confirmed that they have no disagreement with the Board and there is no matter in relation to their retirement that needs to be brought to the attention of the Shareholders of the Company.お知らせ • Apr 06MicroPort Scientific Corporation, Annual General Meeting, May 22, 2024MicroPort Scientific Corporation, Annual General Meeting, May 22, 2024.お知らせ • Mar 19MicroPort Scientific Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024MicroPort Scientific Corporation announced that they will report fiscal year 2023 results on Mar 28, 2024お知らせ • Nov 11MicroPort Scientific Corporation Announces Appointment of Peng Bo as Non-Executive Director and Member of the Strategic CommitteeMicroPort Scientific Corporation announces that Mr. Peng Bo has been appointed as a non-executive Director and a member of the Strategic Committee of the Company with effect from 10 November 2023. Mr. Peng, born in 1968, was the chief marketing officer of the Company and the chairperson of Greater China Executive Committee of the Company. Mr. Peng joined the Group in 2001, and held various positions including market development manager, director of human resources and senior vice president of domestic sales and marketing department in the Group. Mr. Peng has over 24 years of experience in marketing and sales. From December 2021 to November 2023, Mr. Peng served as a non-executive director and chairperson of MicroPort NeuroTech Limited. Mr. Peng also has served as a director and chairperson of Shanghai MicroPort Endovascular MedTech (Group) Co. Ltd. since July 2018, which he has recently applied for resignation with effect from the closing of the forthcoming general meeting of EV MedTech. Mr. Peng received his bachelor's degree in Computer Science from Changchun University of Science and Technology in 1990 and his master's degree in Business Administration from Shanghai University of Finance & Economics in 2003.お知らせ • Aug 18MicroPort Scientific Corporation to Report First Half, 2023 Results on Aug 30, 2023MicroPort Scientific Corporation announced that they will report first half, 2023 results on Aug 30, 2023お知らせ • Jul 12Microport Scientific Corporation Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023MicroPort Scientific Corporation provided consolidated earnings guidance for the six months ended June 30, 2023. For the six months ended 30 June 2023, the revenue of EV MedTech is expected to be between RMB 596.44 million and RMB 633.144 million, representing an increase of between approximately 30% and 38% as compared with the same period last year. The net profit attributable to the equity owners of EV MedTech is expected to be between RMB 268.7956 million and RMB 279.5474 million, representing an increase of between approximately 25% and 30% as compared with the same period last year.お知らせ • Jun 21MicroPort Scientific Corporation Announces Board ChangesThe Board of MicroPort Scientific Corporation announced that Dr. Yasuhisa Kurogi, a non-executive Director of the Company, who did not offer himself for re-election at the AGM in order to allow himself to devote more time to his other endeavours, has retired as a non-executive Director of the Company at the conclusion of the AGM. The Board announced that, with effect from the conclusion of the AGM, Mr. Hiroshi Shirafuji has been elected as a non-executive Director of the Company. His biographical details are set out below: Mr. Shirafuji, born in 1944, is the Honorary Chairman of the Company and a consultant of the Group. Mr. Shirafuji had served as a non-executive Director of the Company from November 2006 to June 2020. Mr. Shirafuji was executive director of Otsuka Medical Devices Co. from January 2017 to March 2017. From February 2011 to January 2017, he served as the President and Representative director of OMD. Prior to joining OMD in February 2011, he was an executive director responsible for pharmaceuticals marketing at Otsuka Pharmaceutical from 1997 to 1998. Mr. Shirafuji joined Otsuka Pharmaceutical in 1967. Mr. Shirafuji received his bachelor's degree in economics from Doshisha University in Kyoto in 1967.お知らせ • May 26MicroPort Scientific Corporation, Annual General Meeting, Jun 19, 2023MicroPort Scientific Corporation, Annual General Meeting, Jun 19, 2023, at 10:00 China Standard Time. Location: 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai 201203 Shangai China Agenda: To receive the audited consolidated financial statements of the Company and the reports of the directors and auditor for the year ended 31 December 2022; to re-elect the following directors of the Company; to elect Mr. Hiroshi Shirafuji as a non-executive Director of the Company; to authorize the board of directors of the Company to fix the respective Directors' remuneration; to re-appoint KPMG as auditor and to authorize the Board to fix its remuneration.お知らせ • Jan 14Microport Scientific Corporation Announces That Hiroshi Shirafuji Has Accepted the Invitation to Act as the Honorary ChairmanMicroPort Scientific Corporation announced that, Mr. Hiroshi Shirafuji ("Mr. Shirafuji") has accepted the invitation to act as the honorary chairman (the "Honorary Chairman") with effect from 13 January 2023. Mr. Shirafuji served as a non-executive director of the Company from November 2006 to June 2020. He witnessed the growth and development of the Company and made substantial contribution to the development of the Group. After retiring as a non-executive director of the Company, Mr. Shirafuji continued to pay attention to the strategy and business development of the Company and put forward constructive opinions and suggestions for the Company. Mr. Shirafuji possesses extensive experience in the medical device industry. The Board believes that the appointment of Mr. Shirafuji as the Honorary Chairman will enable the Company to continuously benefit from his experience and resources in the medical device industry.株主還元MCRP.FUS Medical EquipmentUS 市場7D0%0.4%-1.5%1Y-52.6%-12.6%17.9%株主還元を見る業界別リターン: MCRP.F過去 1 年間で-12.6 % の収益を上げたUS Medical Equipment業界を下回りました。リターン対市場: MCRP.Fは、過去 1 年間で17.9 % のリターンを上げたUS市場を下回りました。価格変動Is MCRP.F's price volatile compared to industry and market?MCRP.F volatilityMCRP.F Average Weekly Movementn/aMedical Equipment Industry Average Movement8.4%Market Average Movement7.2%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.1%安定した株価: MCRP.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のMCRP.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19986,547Jonathon W. Chenwww.microport.comマイクロポート・サイエンティフィック・コーポレーションは、その子会社とともに、中華人民共和国、ヨーロッパ、中東・アフリカ、日本、および世界各国において、医療機器の革新、製造、販売に従事している。同社の心臓血管機器部門は、冠動脈関連疾患治療のための医療ソリューション、冠動脈ステント、関連デリバリーシステム、バルーンカテーテル、アクセサリー、アクティブデバイスを提供している。整形外科機器部門は、再建用関節、脊椎、外傷製品、その他の専門的なインプラントや器具を提供している。心臓リズム管理事業部門では、除細動器、心臓再同期療法機器、ペースメーカーを提供している。血管内・末梢血管デバイス事業では、胸部・腹部大動脈瘤、末梢血管疾患、大動脈解離瘤、その他の動静脈関連疾患のインターベンション治療のための疾患ソリューションを提供している。神経血管デバイス部門は、脳血管疾患用の神経血管治療およびアクセスデバイスを提供している。手術用ロボット事業では、ロボットオントロジー、制御アルゴリズム、電気工学、画像ベースのナビゲーション、精密画像処理からなる手術用ロボットを提供している。手術機器事業では、手術機器を提供している。医療機器の販売にも携わっている。マイクロポート・サイエンティフィック・コーポレーションは1998年に設立され、中華人民共和国の上海に本社を置いている。もっと見るMicroPort Scientific Corporation 基礎のまとめMicroPort Scientific の収益と売上を時価総額と比較するとどうか。MCRP.F 基礎統計学時価総額US$1.61b収益（TTM）US$48.52m売上高(TTM)US$1.11b33.2xPER（株価収益率1.5xP/SレシオMCRP.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MCRP.F 損益計算書（TTM）収益US$1.11b売上原価US$470.80m売上総利益US$634.58mその他の費用US$586.07m収益US$48.52m直近の収益報告Dec 31, 2025次回決算日Aug 31, 2026一株当たり利益（EPS）0.025グロス・マージン57.41%純利益率4.39%有利子負債／自己資本比率103.3%MCRP.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/22 18:56終値2026/06/29 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MicroPort Scientific Corporation 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。19 アナリスト機関Zhe SunBofA Global ResearchYuan GaoChina International Capital Corporation LimitedBo YuChina International Capital Corporation Limited16 その他のアナリストを表示
お知らせ • Aug 19MicroPort Scientific Corporation to Report First Half, 2026 Results on Aug 31, 2026MicroPort Scientific Corporation announced that they will report first half, 2026 results on Aug 31, 2026
お知らせ • Jul 01MicroPort Scientific Corporation Appoints Dr. Yingyao Chen as an Independent Non-executive DirectorMicroPort Scientific Corporation announced that at its AGM held on June 30, 2026, Dr. Yingyao Chen has been elected as an independent non-executive Director of the Company. His biographical details are set out below: Dr. Chen, born in 1968, is an expert in health technology assessment and hospital management. Dr. Chen currently serves as a Professor and Vice Dean of the School of Public Health, Fudan University, Director of the Key Laboratory of Health Technology Assessment of the National Health Commission, Director of the World Health Organization Collaborating Centre for Health Technology Assessment, Chairman of the Health Technology Assessment Professional Committee of the China Medicinal Biotech Association, Chairman of the Health Technology Assessment and Policy Research Professional Committee of the China Association for Medical Devices Industry, Vice Chairman of the Health Technology and Economic Evaluation Professional Committee of the China Health Economics Association, and Vice President of Shanghai Association for Maternal and Child Health and Improving Birth Outcome and Child Development. Dr. Chen has long been engaged in research in health technology assessment, hospital management and public health programme evaluation. He has led a number of research projects of the World Health Organization, the World Bank, the National Health Commission, the National Healthcare Security Administration, among others. Dr. Chen has served as chief editor of a number of national core textbooks, and has published extensively as first author or corresponding author in domestic and international core journals, including the British Medical Journal. From 1991 to 1999, Dr. Chen served as an Assistant Professor and Lecturer at the School of Public Health of Shanghai Medical University. From 1999 to 2001, he was a visiting scholar at the UCLA Fielding School of Public Health. Dr. Chen returned to the School of Public Health of Fudan University in 2001. Dr. Chen obtained his Bachelor's degree in Medicine and Master's degree in Medicine from Shanghai Medical University in 1991 and 1997, respectively, and obtained his Doctoral degree in Management from Fudan University in 2006.
お知らせ • Jun 09MicroPort Scientific Corporation, Annual General Meeting, Jun 30, 2026MicroPort Scientific Corporation, Annual General Meeting, Jun 30, 2026, at 10:00 China Standard Time. Location: 1601 zhangdong road, zhangjiang hi-tech park, shanghai 201203, China
お知らせ • Mar 19MicroPort Scientific Corporation to Report Fiscal Year 2025 Results on Mar 31, 2026MicroPort Scientific Corporation announced that they will report fiscal year 2025 results on Mar 31, 2026
お知らせ • Jan 23MicroPort Scientific Corporation Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025MicroPort Scientific Corporation provided consolidated earnings guidance for the year ended 31 December 2025. The Group is expected to achieve a turnaround to profitability for the year ended 31 December 2025 (the Period), recording a net profit of not less than USD 20 million (for the year ended 31 December 2024: audited net loss of approximately USD 268 million).
お知らせ • Sep 22Shanghai MedTech Medical Equipment Partnership Enterprise completed the acquisition of 7.3% stake in MicroPort Scientific Corporation (SEHK:853) from Otsuka Medical Devices Co., Ltd.Shanghai MedTech Medical Equipment Partnership Enterprise reached an Share Transfer Agreement to acquire 7.3% stake in MicroPort Scientific Corporation (SEHK:853) from Otsuka Medical Devices Co., Ltd. on July 25, 2025. In related transaction, WeTron Capital Limited reached an Share Transfer Agreement to acquire an additional 7.3% stake in MicroPort Scientific from Otsuka Medical Devices and Goal Carol Limited, Jonathan W Chen and Jumbo Glorious Limited reached an Share Transfer Agreement to acquire 1.1% stake in MicroPort Scientific from Otsuka Medical Devices. Following the transaction, Otsuka Medical Devices will hold a 4.99% stake in MicroPort Scientific. The closing shall take place upon obtaining approval from relevant governmental authorities. BofA Securities, Inc. acted as financial advisor to Otsuka Medical Devices Co., Ltd. Shanghai MedTech Medical Equipment Partnership Enterprise completed the acquisition of 7.3% stake in MicroPort Scientific Corporation (SEHK:853) from Otsuka Medical Devices Co., Ltd on September 22, 2025.
お知らせ • Aug 19MicroPort Scientific Corporation to Report First Half, 2026 Results on Aug 31, 2026MicroPort Scientific Corporation announced that they will report first half, 2026 results on Aug 31, 2026
お知らせ • Jul 01MicroPort Scientific Corporation Appoints Dr. Yingyao Chen as an Independent Non-executive DirectorMicroPort Scientific Corporation announced that at its AGM held on June 30, 2026, Dr. Yingyao Chen has been elected as an independent non-executive Director of the Company. His biographical details are set out below: Dr. Chen, born in 1968, is an expert in health technology assessment and hospital management. Dr. Chen currently serves as a Professor and Vice Dean of the School of Public Health, Fudan University, Director of the Key Laboratory of Health Technology Assessment of the National Health Commission, Director of the World Health Organization Collaborating Centre for Health Technology Assessment, Chairman of the Health Technology Assessment Professional Committee of the China Medicinal Biotech Association, Chairman of the Health Technology Assessment and Policy Research Professional Committee of the China Association for Medical Devices Industry, Vice Chairman of the Health Technology and Economic Evaluation Professional Committee of the China Health Economics Association, and Vice President of Shanghai Association for Maternal and Child Health and Improving Birth Outcome and Child Development. Dr. Chen has long been engaged in research in health technology assessment, hospital management and public health programme evaluation. He has led a number of research projects of the World Health Organization, the World Bank, the National Health Commission, the National Healthcare Security Administration, among others. Dr. Chen has served as chief editor of a number of national core textbooks, and has published extensively as first author or corresponding author in domestic and international core journals, including the British Medical Journal. From 1991 to 1999, Dr. Chen served as an Assistant Professor and Lecturer at the School of Public Health of Shanghai Medical University. From 1999 to 2001, he was a visiting scholar at the UCLA Fielding School of Public Health. Dr. Chen returned to the School of Public Health of Fudan University in 2001. Dr. Chen obtained his Bachelor's degree in Medicine and Master's degree in Medicine from Shanghai Medical University in 1991 and 1997, respectively, and obtained his Doctoral degree in Management from Fudan University in 2006.
お知らせ • Jun 09MicroPort Scientific Corporation, Annual General Meeting, Jun 30, 2026MicroPort Scientific Corporation, Annual General Meeting, Jun 30, 2026, at 10:00 China Standard Time. Location: 1601 zhangdong road, zhangjiang hi-tech park, shanghai 201203, China
お知らせ • Mar 19MicroPort Scientific Corporation to Report Fiscal Year 2025 Results on Mar 31, 2026MicroPort Scientific Corporation announced that they will report fiscal year 2025 results on Mar 31, 2026
お知らせ • Jan 23MicroPort Scientific Corporation Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025MicroPort Scientific Corporation provided consolidated earnings guidance for the year ended 31 December 2025. The Group is expected to achieve a turnaround to profitability for the year ended 31 December 2025 (the Period), recording a net profit of not less than USD 20 million (for the year ended 31 December 2024: audited net loss of approximately USD 268 million).
お知らせ • Sep 22Shanghai MedTech Medical Equipment Partnership Enterprise completed the acquisition of 7.3% stake in MicroPort Scientific Corporation (SEHK:853) from Otsuka Medical Devices Co., Ltd.Shanghai MedTech Medical Equipment Partnership Enterprise reached an Share Transfer Agreement to acquire 7.3% stake in MicroPort Scientific Corporation (SEHK:853) from Otsuka Medical Devices Co., Ltd. on July 25, 2025. In related transaction, WeTron Capital Limited reached an Share Transfer Agreement to acquire an additional 7.3% stake in MicroPort Scientific from Otsuka Medical Devices and Goal Carol Limited, Jonathan W Chen and Jumbo Glorious Limited reached an Share Transfer Agreement to acquire 1.1% stake in MicroPort Scientific from Otsuka Medical Devices. Following the transaction, Otsuka Medical Devices will hold a 4.99% stake in MicroPort Scientific. The closing shall take place upon obtaining approval from relevant governmental authorities. BofA Securities, Inc. acted as financial advisor to Otsuka Medical Devices Co., Ltd. Shanghai MedTech Medical Equipment Partnership Enterprise completed the acquisition of 7.3% stake in MicroPort Scientific Corporation (SEHK:853) from Otsuka Medical Devices Co., Ltd on September 22, 2025.
お知らせ • Aug 19MicroPort Scientific Corporation to Report First Half, 2025 Results on Aug 29, 2025MicroPort Scientific Corporation announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • Jul 18Microport Scientific Corporation Provides Earnings Guidance for the Six Month Ended 30 June 2025MicroPort Scientific Corporation provided earnings guidance for the six month ended 30 June 2025. The Group is estimated the revenue of the Group slightly decreased by no more than 4% year-on-year (excluding the effect of exchange rate). Among them, except the surgical robot business, all of the other major business segments recorded revenue decline or growth slowdown to varying extents.
お知らせ • Apr 30Shanghai Fund Is Said to Weigh Buying Otsuka’s Stake in MicroPortA fund backed by Shanghai Industrial Investment (Holding) Co., Ltd. is in talks to buy Otsuka Holdings Co., Ltd. (TSE:4578)’s stake in Chinese medical device maker MicroPort Scientific Corporation (SEHK:853), according to people familiar with the situation. Otsuka has been considering options for its holding in Hong Kong-listed MicroPort, including selling it, Bloomberg News reported in October. The Japanese drugmaker’s stake was about 20.9% as of the end of June.
お知らせ • Apr 29MicroPort Scientific Corporation, Annual General Meeting, May 30, 2025MicroPort Scientific Corporation, Annual General Meeting, May 30, 2025, at 10:00 China Standard Time. Location: 1601 zhangdong road, zhangjiang hi-tech park, shanghai 201203, China
お知らせ • Mar 18MicroPort Scientific Corporation to Report Fiscal Year 2024 Results on Mar 28, 2025MicroPort Scientific Corporation announced that they will report fiscal year 2024 results on Mar 28, 2025
お知らせ • Aug 20MicroPort Scientific Corporation to Report First Half, 2024 Results on Aug 30, 2024MicroPort Scientific Corporation announced that they will report first half, 2024 results on Aug 30, 2024
お知らせ • Jul 30MicroPort Scientific Corporation Announces Firesorb Bioresorbable Coronary Scaffold System Obtained Approval for Marketing from the NMPAThe board of directors of MicroPort Scientific Corporation announced that on 30 July 2024, the new generation Firesorb Bioresorbable Scaffold System (‘Firesorb Stent’), self- developed by the Group, obtained the approval for marketing from the National Medical Products Administration of China (the ‘NMPA’), which will further improve the Group's integrated, precise and intelligent holistic solutions for the diagnosis and treatment of coronary artery-related diseases, in order to serve the comprehensive needs of patients worldwide. About Firesorb Stent: First Target Eluting Bioresorbable Scaffold System with Reduced Strut Thickness to Same Level as Metal Stents While Maintaining Equal Support The Group adopted thin strut design which made Firesorb Stent the first target eluting bioresorbable scaffold system with reduced strut thickness to same level as metal stents while maintaining equal support. The Rate of Thrombosis of All Patients in the FUTURE-I, II and III Three Trials was only 0.32% at 2-year Follow up, with a Four-year Thrombotic Event of 0% in the RCT Study Data from large preclinical studies have shown that Firesorb Stent is non-inferior to permanent drug-eluting stents in terms of major clinical parameters from publicly available clinical data. Firesorb Stent has a target lesion failure (TLF) rate of only 4.3% at 4-year follow-up of RCT study. The rate of thrombosis of all patients in the FUTURE-I, II, and III Trials was only 0.32% at 2-year follow up, with four-year thrombotic event of 0% in the RCT study. The imaging results supports that Firesorb Stent is not inferior to other marketed permanent stents in terms of endothelial coverage rate and speed, and the numerical results of the clinical trial are superior compared to other biodegradable stents. Target Eluting Technology to Reduce Effective Drug Load while Achieving Same Efficacy Adopting the unique ‘target eluting’ technology of MicroPort, Firesorb Stent achieves precisely targeted drug application, coating only one side of the stent facing the vessel wall and reducing the effective drug load to one-third of the universal drug load while achieving the same efficacy. Wider Lesion Size Coverage As a bioresorbable stent with wider lesion size coverage and applicable to the treatment of small- vessel lesions up to 2.5 millimeters in diameter, Firesorb Stent solves the problem of accessibility of bioresorbable stent in small-vessel lesion areas. Meanwhile, the guidewire for rotational atherectomy, which is used in conjunction with the Group's first self-developed rotational atherectomy catheter system and coronary rotational atherectomy system, has recently obtained marketing approval from the NMPA, and the coronary rotational atherectomy system has entered the NMPA special review approval process for innovative medical devices (the ‘Green Path’). Impact on the Company. Improve the Diagnosis Holistic Medical Solutions for the Treatment of Cardiovascular Diseases to Bring New Growth Momentum The marketing approval of Firesorb Stent and guidewire for rotational atherectomy by the NMPA will further improve the Group's integrated, precise and intelligent holistic solutions for the diagnosis and treatment of coronary artery-related diseases, in order to serve the comprehensive needs of patients worldwide. Leveraging on the commercialisation capability of the Group's existing cardiovascular interventional product channels and overseas platforms, it is believed that new growth momentum will be brought to the Group. Strengthen the Leading Position in the Global Coronary Stent Field The incidence of coronary heart disease is trending younger. Bioresorbable stents, which can support diseased blood vessels in the short term and degrade completely in the body in the long term, are at the scientific and technological hub amid the global competition. The approval of Firesorb Stent will further strengthen the Group's leading position in the global coronary stent field. Application of Technologies Derived from Platform The technologies derived from Firesorb Stent platform are expected to be applied in other areas such as cerebral infarction, peripheral vascular stenosis, and bone trauma in the future, allowing more patients to access internationally leading treatment solutions.
お知らせ • May 23Microport Scientific Corporation Announces Retirement of Non-Executive DirectorsThe Board of MicroPort Scientific Corporation announced that Dr. Qiyi Luo and Mr. Bo Peng, being non-executive directors of the Company, who did not offer themselves for re-election at the AGM in order to allow themselves to devote more time to their personal endeavours, have retired as non-executive directors of the Company at the conclusion of the AGM. Meanwhile, Dr. Qiyi Luo and Mr. Bo Peng have resigned as members of the strategy committee (the "Strategy Committee") of the Board at the conclusion of the AGM. Dr. Qiyi Luo and Mr. Bo Peng have confirmed that they have no disagreement with the Board and there is no matter in relation to their retirement that needs to be brought to the attention of the Shareholders of the Company.
お知らせ • Apr 06MicroPort Scientific Corporation, Annual General Meeting, May 22, 2024MicroPort Scientific Corporation, Annual General Meeting, May 22, 2024.
お知らせ • Mar 19MicroPort Scientific Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024MicroPort Scientific Corporation announced that they will report fiscal year 2023 results on Mar 28, 2024
お知らせ • Nov 11MicroPort Scientific Corporation Announces Appointment of Peng Bo as Non-Executive Director and Member of the Strategic CommitteeMicroPort Scientific Corporation announces that Mr. Peng Bo has been appointed as a non-executive Director and a member of the Strategic Committee of the Company with effect from 10 November 2023. Mr. Peng, born in 1968, was the chief marketing officer of the Company and the chairperson of Greater China Executive Committee of the Company. Mr. Peng joined the Group in 2001, and held various positions including market development manager, director of human resources and senior vice president of domestic sales and marketing department in the Group. Mr. Peng has over 24 years of experience in marketing and sales. From December 2021 to November 2023, Mr. Peng served as a non-executive director and chairperson of MicroPort NeuroTech Limited. Mr. Peng also has served as a director and chairperson of Shanghai MicroPort Endovascular MedTech (Group) Co. Ltd. since July 2018, which he has recently applied for resignation with effect from the closing of the forthcoming general meeting of EV MedTech. Mr. Peng received his bachelor's degree in Computer Science from Changchun University of Science and Technology in 1990 and his master's degree in Business Administration from Shanghai University of Finance & Economics in 2003.
お知らせ • Aug 18MicroPort Scientific Corporation to Report First Half, 2023 Results on Aug 30, 2023MicroPort Scientific Corporation announced that they will report first half, 2023 results on Aug 30, 2023
お知らせ • Jul 12Microport Scientific Corporation Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023MicroPort Scientific Corporation provided consolidated earnings guidance for the six months ended June 30, 2023. For the six months ended 30 June 2023, the revenue of EV MedTech is expected to be between RMB 596.44 million and RMB 633.144 million, representing an increase of between approximately 30% and 38% as compared with the same period last year. The net profit attributable to the equity owners of EV MedTech is expected to be between RMB 268.7956 million and RMB 279.5474 million, representing an increase of between approximately 25% and 30% as compared with the same period last year.
お知らせ • Jun 21MicroPort Scientific Corporation Announces Board ChangesThe Board of MicroPort Scientific Corporation announced that Dr. Yasuhisa Kurogi, a non-executive Director of the Company, who did not offer himself for re-election at the AGM in order to allow himself to devote more time to his other endeavours, has retired as a non-executive Director of the Company at the conclusion of the AGM. The Board announced that, with effect from the conclusion of the AGM, Mr. Hiroshi Shirafuji has been elected as a non-executive Director of the Company. His biographical details are set out below: Mr. Shirafuji, born in 1944, is the Honorary Chairman of the Company and a consultant of the Group. Mr. Shirafuji had served as a non-executive Director of the Company from November 2006 to June 2020. Mr. Shirafuji was executive director of Otsuka Medical Devices Co. from January 2017 to March 2017. From February 2011 to January 2017, he served as the President and Representative director of OMD. Prior to joining OMD in February 2011, he was an executive director responsible for pharmaceuticals marketing at Otsuka Pharmaceutical from 1997 to 1998. Mr. Shirafuji joined Otsuka Pharmaceutical in 1967. Mr. Shirafuji received his bachelor's degree in economics from Doshisha University in Kyoto in 1967.
お知らせ • May 26MicroPort Scientific Corporation, Annual General Meeting, Jun 19, 2023MicroPort Scientific Corporation, Annual General Meeting, Jun 19, 2023, at 10:00 China Standard Time. Location: 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai 201203 Shangai China Agenda: To receive the audited consolidated financial statements of the Company and the reports of the directors and auditor for the year ended 31 December 2022; to re-elect the following directors of the Company; to elect Mr. Hiroshi Shirafuji as a non-executive Director of the Company; to authorize the board of directors of the Company to fix the respective Directors' remuneration; to re-appoint KPMG as auditor and to authorize the Board to fix its remuneration.
お知らせ • Jan 14Microport Scientific Corporation Announces That Hiroshi Shirafuji Has Accepted the Invitation to Act as the Honorary ChairmanMicroPort Scientific Corporation announced that, Mr. Hiroshi Shirafuji ("Mr. Shirafuji") has accepted the invitation to act as the honorary chairman (the "Honorary Chairman") with effect from 13 January 2023. Mr. Shirafuji served as a non-executive director of the Company from November 2006 to June 2020. He witnessed the growth and development of the Company and made substantial contribution to the development of the Group. After retiring as a non-executive director of the Company, Mr. Shirafuji continued to pay attention to the strategy and business development of the Company and put forward constructive opinions and suggestions for the Company. Mr. Shirafuji possesses extensive experience in the medical device industry. The Board believes that the appointment of Mr. Shirafuji as the Honorary Chairman will enable the Company to continuously benefit from his experience and resources in the medical device industry.
